The iron-y of iron overload and iron deficiency in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 9, 2017, Pages 1103-1112

  Cloonan, Suzanne M ^a   Mumby, Sharon ^b   Adcock, Ian M ^b   Choi, Augustine M K ^a,c   Chung, Kian Fan ^b   Quinlan, Gregory J ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Airway Disease   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; IRON CHELATING AGENT;

ANEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; HUMAN; IRON DEFICIENCY; IRON HOMEOSTASIS; IRON OVERLOAD; LUNG INFECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SMOKING; COMORBIDITY; DEFICIENCY; HOMEOSTASIS; INHALATIONAL DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; LUNG; METABOLISM;

ADMINISTRATION, INHALATION; ANEMIA, IRON-DEFICIENCY; COMORBIDITY; HOMEOSTASIS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 85019972952     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201702-0311PP     Document Type: Review

References (127)

1. Burney PG, Patel J, Newson R, Minelli C, Naghavi M. Global and regional trends in COPD mortality, 1990-2010. Eur Respir J 2015;45: 1239-1247.
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-773.
3. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012;379:1341-1351.
4. Mortimer K, Gordon SB, Jindal SK, Accinelli RA, Balmes J, Martin WJ II. Household air pollution is a major avoidable risk factor for cardiorespiratory disease. Chest 2012;142:1308-1315.
5. DeMeo DL, Mariani T, Bhattacharya S, Srisuma S, Lange C, Litonjua A, Bueno R, Pillai SG, Lomas DA, Sparrow D, et al. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet 2009;85:493-502.
6. Chappell SL, Daly L, Lotya J, Alsaegh A, Guetta-Baranes T, Roca J, Rabinovich R, Morgan K, Millar AB, Donnelly SC, et al. The role of IREB2 and transforming growth factor b-1 genetic variants in COPD: a replication case-control study. BMC Med Genet 2011;12:24.
7. Du Y, Xue Y, Xiao W. Association of IREB2 gene rs2568494 polymorphism with risk of chronic obstructive pulmonary disease: a meta-analysis. Med Sci Monit 2016;22:177-182.
8. Hardin M, Zielinski J, Wan ES, Hersh CP, Castaldi PJ, Schwinder E, Hawrylkiewicz I, Sliwinski P, Cho MH, Silverman EK. CHRNA3/5, IREB2, and ADCY2 are associated with severe chronic obstructive pulmonary disease in Poland. Am J Respir Cell Mol Biol 2012;47:203-208.
9. Ding Y, Yang D, Xun X, Wang Z, Sun P, Xu D, He P, Niu H, Jin T. Association of genetic polymorphisms with chronic obstructive pulmonary disease in the Hainan population: a case-control study. Int J Chron Obstruct Pulmon Dis 2014;10:7-13.
10. Ghio AJ. Disruption of iron homeostasis and lung disease. Biochim Biophys Acta 2009;1790:731-739.
11. Kurz T, Gustafsson B, Brunk UT. Cell sensitivity to oxidative stress is influenced by ferritin autophagy. Free Radic Biol Med 2011;50:1647-1658.
12. Ballweg K, Mutze K, Königshoff M, Eickelberg O, Meiners S. Cigarette smoke extract affects mitochondrial function in alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2014;307:L895-L907.
13. Ito S, Araya J, Kurita Y, Kobayashi K, Takasaka N, Yoshida M, Hara H, Minagawa S, Wakui H, Fujii S, et al. PARK2-mediated mitophagy is involved in regulation of HBEC senescence in COPD pathogenesis. Autophagy 2015;11:547-559.
14. Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol 2015;15:500-510.
15. John M, Lange A, Hoernig S, Witt C, Anker SD. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol 2006;111:365-370.
16. Martinez-Rivera C, Portillo K, Muñoz-Ferrer A, Martinez-Ortiz ML, Molins E, Serra P, Ruiz-Manzano J, Morera J. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD 2012;9:243-250.
17. Boutou AK, Karrar S, Hopkinson NS, Polkey MI. Anemia and survival in chronic obstructive pulmonary disease: a dichotomous rather than a continuous predictor. Respiration 2013;85:126-131.
18. Nickol AH, Frise MC, Cheng HY, McGahey A, McFadyen BM, Harris-Wright T, Bart NK, Curtis MK, Khandwala S, O'Neill DP, et al. A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary disease. BMJ Open 2015;5:e007911.
19. Mackay AJLM, Branigan BS, Baribaud F, George SN, Donaldson GC, Wedzicha JA. Serum amyloid A and hepcidin elevations characterise bacterial-associated exacerbations in frequently exacerbating COPD patients [abstract]. Am J Respir Crit Care Med 2015;191:A6336.
20. Takemoto K, Kawai H, Kuwahara T, Nishina M, Adachi S. Metal concentrations in human lung tissue, with special reference to age, sex, cause of death, emphysema and contamination of lung tissue. Int Arch Occup Environ Health 1991;62:579-586.
21. Dez M, Arroyo M, Cerdan FJ, Muñoz M, Martin MA, Balibrea JL. Serum and tissue trace metal levels in lung cancer. Oncology 1989;46:230-234.
22. Sirlin CB, Reeder SB. Magnetic resonance imaging quantification of liver iron. Magn Reson Imaging Clin N Am 2010;18:359-381.
23. Van Eijk HG, Wiltink WF, Bos G, Goossens JP. Measurement of the iron content in human liver specimens. Clin Chim Acta 1974;50:275-280.
24. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, et al. On T2∗ magnetic resonance and cardiac iron. Circulation 2011;123:1519-1528.
25. World Health Organization (WHO). Guidelines for drinking-water quality. 2nd ed. Geneva: WHO; 1996.
26. Ghio AJ, Carter JD, Richards JH, Richer LD, Grissom CK, Elstad MR. Iron and iron-related proteins in the lower respiratory tract of patients with acute respiratory distress syndrome. Crit Care Med 2003;31:395-400.
27. Kim J, Molina RM, Donaghey TC, Buckett PD, Brain JD, Wessling-Resnick M. Influence of DMT1 and iron status on inflammatory responses in the lung. Am J Physiol Lung Cell Mol Physiol 2011;300: L659-L665.
28. Du Y, Guo M, Whitsett JA, Xu Y. 'LungGENS': a web-based tool for mapping single-cell gene expression in the developing lung. Thorax 2015;70:1092-1094.
29. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Sjostedt E, Asplund A, et al. Tissue-based map of the human proteome. Science 2015;347: 1260419.
30. Lindskog C, Fagerberg L, Hallstrom B, Edlund K, Hellwig B, Rahnenfuhrer J, Kampf C, Uhlen M, Ponten F, Micke P. The lung-specific proteome defined by integration of transcriptomics and antibody-based profiling. FASEB J 2014;28:5184-5196.
31. Heilig EA, Thompson KJ, Molina RM, Ivanov AR, Brain JD, Wessling-Resnick M. Manganese and iron transport across pulmonary epithelium. Am J Physiol Lung Cell Mol Physiol 2006;290: L1247-L1259.
32. Wu L, Ma L, Nicholson LF, Black PN. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med 2011;105:329-336.
33. Cloonan SM, Glass K, Laucho-Contreras ME, Bhashyam AR, Cervo M, Pabon MA, Konrad C, Polverino F, Siempos II, Perez E, et al. Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice. Nat Med 2016;22:163-174.
34. Szabo S, Barbu Z, Lakatos L, Laszlo I, Szabo A. Local production of proteins in normal human bronchial secretion. Respiration 1980;39: 172-178.
35. Fracchia A, Ubbiali A, El Bitar O, Pacetti M, Sommariva E, Arreghini M, Longhini E, Bonalumi GP. A comparative study on ferritin concentration in serum and bilateral bronchoalveolar lavage fluid of patients with peripheral lung cancer versus control subjects. Oncology 1999;56:181-188.
36. Ghio AJ, Carter JD, Dailey LA, Devlin RB, Samet JM. Respiratory epithelial cells demonstrate lactoferrin receptors that increase after metal exposure. Am J Physiol 1999;276:L933-L940.
37. Kono S, Yoshida K, Tomosugi N, Terada T, Hamaya Y, Kanaoka S, Miyajima H. Biological effects of mutant ceruloplasmin on hepcidin-mediated internalization of ferroportin. Biochim Biophys Acta 2010; 1802:968-975.
38. Iwamoto H, Gao J, Koskela J, Kinnula V, Kobayashi H, Laitinen T, Mazur W. Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur Respir J 2014;43:421-429.
39. Yang F, Haile DJ, Wang X, Dailey LA, Stonehuerner JG, Ghio AJ. Apical location of ferroportin 1 in airway epithelia and its role in iron detoxification in the lung. Am J Physiol Lung Cell Mol Physiol 2005; 289:L14-L23.
40. Arezes J, Nemeth E. Hepcidin and iron disorders: new biology and clinical approaches. Int J Lab Hematol 2015;37:92-98.
41. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006;38:531-539.
42. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271-1276.
43. Nguyen NB, Callaghan KD, Ghio AJ, Haile DJ, Yang F. Hepcidin expression and iron transport in alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2006;291:L417-L425.
44. Carraway MS, Ghio AJ, Taylor JL, Piantadosi CA. Induction of ferritin and heme oxygenase-1 by endotoxin in the lung. Am J Physiol 1998; 275:L583-L592.
45. Damron FH, Oglesby-Sherrouse AG, Wilks A, Barbier M. Dual-seq transcriptomics reveals the battle for iron during Pseudomonas aeruginosa acute murine pneumonia. Sci Rep 2016;6:39172.
46. Seifert M, Nairz M, Schroll A, Schrettl M, Haas H, Weiss G. Effects of the Aspergillus fumigatus siderophore systems on the regulation of macrophage immune effector pathways and iron homeostasis. Immunobiology 2008;213:767-778.
47. Galván-Peña S, O'Neill LA. Metabolic reprograming in macrophage polarization. Front Immunol 2014;5:420.
48. Recalcati S, Locati M, Gammella E, Invernizzi P, Cairo G. Iron levels in polarized macrophages: regulation of immunity and autoimmunity. Autoimmun Rev 2012;11:883-889.
49. Thompson AB, Bohling T, Heires A, Linder J, Rennard SI. Lower respiratory tract iron burden is increased in association with cigarette smoking. J Lab Clin Med 1991;117:493-499.
50. Mussalo-Rauhamaa H, Leppänen A, Salmela SS, Pyysalo H. Cigarettes as a source of some trace and heavy metals and pesticides in man. Arch Environ Health 1986;41:49-55.
51. Ghio AJ, Hilborn ED, Stonehuerner JG, Dailey LA, Carter JD, Richards JH, Crissman KM, Foronjy RF, Uyeminami DL, Pinkerton KE. Particulate matter in cigarette smoke alters iron homeostasis to produce a biological effect. Am J Respir Crit Care Med 2008;178:1130-1138.
52. Mateos F, Brock JH, Pérez-Arellano JL. Iron metabolism in the lower respiratory tract. Thorax 1998;53:594-600.
53. Corhay JL, Weber G, Bury T, Mariz S, Roelandts I, Radermecker MF. Iron content in human alveolar macrophages. Eur Respir J 1992;5:804-809.
54. McGowan SE, Henley SA. Iron and ferritin contents and distribution in human alveolar macrophages. J Lab Clin Med 1988;111:611-617.
55. Philippot Q, Deslée G, Adair-Kirk TL, Woods JC, Byers D, Conradi S, Dury S, Perotin JM, Lebargy F, Cassan C, et al. Increased iron sequestration in alveolar macrophages in chronic obstructive pulmonary disease. PLoS One 2014;9:e96285.
56. Wesselius LJ, Flowers CH, Skikne BS. Alveolar macrophage content of isoferritins and transferrin: comparison of nonsmokers and smokers with and without chronic airflow obstruction. Am Rev Respir Dis 1992;145:311-316.
57. Wesselius LJ, Nelson ME, Skikne BS. Increased release of ferritin and iron by iron-loaded alveolar macrophages in cigarette smokers. Am J Respir Crit Care Med 1994;150:690-695.
58. Nelson ME, O'Brien-Ladner AR, Wesselius LJ. Regional variation in iron and iron-binding proteins within the lungs of smokers. Am J Respir Crit Care Med 1996;153:1353-1358.
59. Mumby S, Saito J, Adcock IM, Chung KF, Quinlan GJ. Decreased breath excretion of redox active iron in COPD: a protective failure? Eur Respir J 2016;47:1267-1270.
60. Lee CH, Goag EK, Lee SH, Chung KS, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Song JH. Association of serum ferritin levels with smoking and lung function in the Korean adult population: analysis of the fourth and fifth Korean National Health and Nutrition Examination Survey. Int J Chron Obstruct Pulmon Dis 2016;11:3001-3006.
61. Shibata Y, Inoue S, Igarashi A, Yamauchi K, Abe S, Aida Y, Nunomiya K, Sato M, Nakano H, Sato K, et al. Elevated serum iron is a potent biomarker for spirometric resistance to cigarette smoke among Japanese males: the Takahata study. PLoS One 2013;8:e74020.
62. McKeever TM, Lewis SA, Smit HA, Burney P, Cassano PA, Britton J. A multivariate analysis of serum nutrient levels and lung function. Respir Res 2008;9:67.
63. Smith JR, Landaw SA. Smokers' polycythemia. N Engl J Med 1978; 298:6-10.
64. Nordenberg D, Yip R, Binkin NJ. The effect of cigarette smoking on hemoglobin levels and anemia screening. JAMA 1990;264:1556-1559.
65. Leifert JA. Anaemia and cigarette smoking. Int J Lab Hematol 2008;30: 177-184.
66. Sadreameli SC, Kopp BT, Creary SE, Eakin MN, McGrath-Morrow S, Strouse JJ. Secondhand smoke is an important modifiable risk factor in sickle cell disease: a review of the current literature and areas for future research. Int J Environ Res Public Health 2016;13:1131.
67. Cohen RT, Strunk RC, Field JJ, Rosen CL, Kirkham FJ, Redline S, Stocks J, Rodeghier MJ, DeBaun MR. Environmental tobacco smoke and airway obstruction in children with sickle cell anemia. Chest 2013;144:1323-1329.
68. Pacht ER, Davis WB. Decreased ceruloplasmin ferroxidase activity in cigarette smokers. J Lab Clin Med 1988;111:661-668.
69. Ingebrigtsen T, Thomsen SF, Vestbo J, van der Sluis S, Kyvik KO, Silverman EK, Svartengren M, Backer V. Genetic influences on chronic obstructive pulmonary disease-a twin study. Respir Med 2010;104:1890-1895.
70. Lee JH, Cho MH, Hersh CP, McDonald ML, Wells JM, Dransfield MT, Bowler RP, Lynch DA, Lomas DA, Crapo JD, et al.; COPDGene and ECLIPSE Investigators. IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2015;52:365-376.
71. Kim WJ, Wood AM, Barker AF, Brantly ML, Campbell EJ, Eden E, McElvaney G, Rennard SI, Sandhaus RA, Stocks JM, et al. Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respir Res 2012;13:16.
72. Siedlinski M, Tingley D, Lipman PJ, Cho MH, Litonjua AA, Sparrow D, Bakke P, Gulsvik A, Lomas DA, Anderson W, et al.; COPDGene and ECLIPSE Investigators. Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. Hum Genet 2013;132:431-441.
73. Zhou H, Yang J, Li D, Xiao J, Wang B, Wang L, Ma C, Xu S, Ou X, Feng Y. Association of IREB2 and CHRNA3/5 polymorphisms with COPD and COPD-related phenotypes in a Chinese Han population. J Hum Genet 2012;57:738-746.
74. Ziółkowska-Suchanek I, Mosor M, Gabryel P, Grabicki M, Zurawek M, Fichna M, Strauss E, Batura-Gabryel H, Dyszkiewicz W, Nowak J. Susceptibility loci in lung cancer and COPD: association of IREB2 and FAM13A with pulmonary diseases. Sci Rep 2015;5:13502.
75. Liu Y, Kheradmand F, Davis CF, Scheurer ME, Wheeler D, Tsavachidis S, Armstrong G, Simpson C, Mandal D, Kupert E, et al. Focused analysis of exome sequencing data for rare germline mutations in familial and sporadic lung cancer. J Thorac Oncol 2016;11:52-61.
76. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, et al.; ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009;5: e1000421.
77. Saccone NL, Culverhouse RC, Schwantes-An TH, Cannon DS, Chen X, Cichon S, Giegling I, Han S, Han Y, Keskitalo-Vuokko K, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet 2010;6:6.
78. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, Manolescu A, Thorleifsson G, Stefansson H, Ingason A, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-642.
79. He JQ, Foreman MG, Shumansky K, Zhang X, Akhabir L, Sin DD, Man SF, DeMeo DL, Litonjua AA, Silverman EK, et al. Associations of IL6 polymorphisms with lung function decline and COPD. Thorax 2009;64:698-704.
80. Ghio AJ, Soukup JM, Richards JH, Fischer BM, Voynow JA, Schmechel DE. Deficiency of a-1-antitrypsin influences systemic iron homeostasis. Int J Chron Obstruct Pulmon Dis 2013;8:45-51.
81. Fischer BM, Domowicz DA, Zheng S, Carter JL, McElvaney NG, Taggart C, Lehmann JR, Voynow JA, Ghio AJ. Neutrophil elastase increases airway epithelial nonheme iron levels. Clin Transl Sci 2009;2:333-339.
82. Lam M, Torbenson M, Yeh MM, Vivekanandan P, Ferrell L. HFE mutations in alpha-1-antitrypsin deficiency: an examination of cirrhotic explants. Mod Pathol 2010;23:637-643.
83. Linet MS, Gridley G, Nyrén O, Mellemkjaer L, Olsen JH, Keehn S, Adami HO, Fraumeni JF Jr. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol 1999;149:1010-1015.
84. Bala S, Tabaku A. Chronic obstructive pulmonary disease in iron-steel and ferrochrome industry workers. Cent Eur J Public Health 2010;18:93-98.
85. Hedlund U, Järvholm B, Lundbäck B. Persistence of respiratory symptoms in ex-underground iron ore miners. Occup Med (Lond) 2006;56:380-385.
86. Adelroth E, Hedlund U, Blomberg A, Helleday R, Ledin MC, Levin JO, Pourazar J, Sandström T, Järvholm B. Airway inflammation in iron ore miners exposed to dust and diesel exhaust. Eur Respir J 2006; 27:714-719.
87. Hedlund U, Järvholm B, Lundbäck B. Respiratory symptoms and obstructive lung diseases in iron ore miners: report from the obstructive lung disease in northern Sweden studies. Eur J Epidemiol 2004;19:953-958.
88. Hirayama F, Lee AH, Oura A, Mori M, Hiramatsu N, Taniguchi H. Dietary intake of six minerals in relation to the risk of chronic obstructive pulmonary disease. Asia Pac J Clin Nutr 2010;19:572-577.
89. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011;12:146.
90. Portillo K, Martinez-Rivera C, Ruiz-Manzano J. Anaemia in chronic obstructive pulmonary disease: does it really matter? Int J Clin Pract 2013;67:558-565.
91. Tandara L, Grubisic TZ, Ivan G, Jurisic Z, Tandara M, Gugo K, Mladinov S, Salamunic I. Systemic inflammation up-regulates serum hepcidin in exacerbations and stabile chronic obstructive pulmonary disease. Clin Biochem 2015;48:1252-1257.
92. Silverberg DS, Mor R, Weu MT, Schwartz D, Schwartz IF, Chernin G. Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med 2014;14:24.
93. Plesner LL, Schoos MM, Dalsgaard M, Goetze JP, Kjøller E, Vestbo J, Iversen K. Iron deficiency in COPD associates with increased pulmonary artery pressure estimated by echocardiography. Heart Lung Circ 2017;26:101-104.
94. Frise MC, Cheng HY, Nickol AH, Curtis MK, Pollard KA, Roberts DJ, Ratcliffe PJ, Dorrington KL, Robbins PA. Clinical iron deficiency disturbs normal human responses to hypoxia. J Clin Invest 2016;126:2139-2150.
95. Boutou AK, Polkey MI, Hopkinson NS. Non-anaemic iron deficiency in COPD: a potential therapeutic target? Respirology 2015;20:1004-1005.
96. Barberan-Garcia A, Rodŕiguez DA, Blanco I, Gea J, Torralba Y, Arbillaga-Etxarri A, Barberà JA, Vilaró J, Roca J, Orozco-Levi M. Non-anaemic iron deficiency impairs response to pulmonary rehabilitation in COPD. Respirology 2015;20:1089-1095.
97. Huang ML, Lane DJ, Richardson DR. Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease. Antioxid Redox Signal 2011;15:3003-3019.
98. Chen C, Paw BH. Cellular and mitochondrial iron homeostasis in vertebrates. Biochim Biophys Acta 2012;1823:1459-1467.
99. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008;31:1334-1356.
100. Wiegman CH, Michaeloudes C, Haji G, Narang P, Clarke CJ, Russell KE, Bao W, Pavlidis S, Barnes PJ, Kanerva J, et al.; COPDMAP. Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2015; 136:769-780.
101. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006;28:219-242.
102. Kamp DW, Greenberger MJ, Sbalchierro JS, Preusen SE, Weitzman SA. Cigarette smoke augments asbestos-induced alveolar epithelial cell injury: role of free radicals. Free Radic Biol Med 1998;25: 728-739.
103. Wesselius LJ, Williams WL, Bailey K, Vamos S, O'Brien-Ladner AR, Wiegmann T. Iron uptake promotes hyperoxic injury to alveolar macrophages. Am J Respir Crit Care Med 1999;159:100-106.
104. Dai J, Xie C, Churg A. Iron loading makes a nonfibrogenic model air pollutant particle fibrogenic in rat tracheal explants. Am J Respir Cell Mol Biol 2002;26:685-693.
105. Smith LA, Paszkiewicz GM, Hutson AD, Pauly JL. Inflammatory response of lung macrophages and epithelial cells to tobacco smoke: a literature review of ex vivo investigations. Immunol Res 2010;46:94-126.
106. Gally F, Chu HW, Bowler RP. Cigarette smoke decreases airway epithelial FABP5 expression and promotes Pseudomonas aeruginosa infection. PLoS One 2013;8:e51784.
107. Ghio AJ, Soukup JM, Dailey LA, Tong H, Kesic MJ, Budinger GR, Mutlu GM. Wood smoke particle sequesters cell iron to impact a biological effect. Chem Res Toxicol 2015;28:2104-2111.
108. Mizumura K, Cloonan SM, Nakahira K, Bhashyam AR, Cervo M, Kitada T, Glass K, Owen CA, Mahmood A, Washko GR, et al. Mitophagy-dependent necroptosis contributes to the pathogenesis of COPD. J Clin Invest 2014;124:3987-4003.
109. Brunk UT, Neuzil J, Eaton JW. Lysosomal involvement in apoptosis. Redox Rep 2001;6:91-97.
110. Huang ML, Becker EM, Whitnall M, Suryo Rahmanto Y, Ponka P, Richardson DR. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci USA 2009;106:16381-16386.
111. Yatmark P, Morales NP, Chaisri U, Wichaiyo S, Hemstapat W, Srichairatanakool S, Svasti S, Fucharoen S. Effects of iron chelators on pulmonary iron overload and oxidative stress in b-thalassemic mice. Pharmacology 2015;96:192-199.
112. Sohn YS, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 2008;111:1690-1699.
113. Filosa A, Vitrano A, Rigano P, Calvaruso G, Barone R, Capra M, Cuccia L, Gagliardotto F, Pitrolo L, Prossomariti L, et al. Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major. Blood Cells Mol Dis 2013;51:85-88.
114. Zhou T, Ma Y, Kong X, Hider RC. Design of iron chelators with therapeutic application. Dalton Trans 2012;41:6371-6389.
115. Schönhofer B, Wenzel M, Geibel M, Köhler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med 1998;26:1824-1828.
116. Schönhofer B, Böhrer H, Köhler D. Blood transfusion facilitating difficult weaning from the ventilator. Anaesthesia 1998;53: 181-184.
117. John M, Hoernig S, Doehner W, Okonko DD, Witt C, Anker SD. Anemia and inflammation in COPD. Chest 2005;127:825-829.
118. Boutou AK, Pitsiou GG, Stanopoulos I, Kontakiotis T, Kyriazis G, Argyropoulou P. Levels of inflammatory mediators in chronic obstructive pulmonary disease patients with anemia of chronic disease: a case-control study. QJM 2012;105:657-663.
119. Tassiopoulos S, Kontos A, Konstantopoulos K, Hadzistavrou C, Vaiopoulos G, Aessopos A, Tassiopoulos T. Erythropoietic response to hypoxaemia in diffuse idiopathic pulmonary fibrosis, as opposed to chronic obstructive pulmonary disease. Respir Med 2001;95:471-475.
120. Sala E, Balaguer C, Villena C, Ŕios A, Noguera A, Núñez B, Agusti A. Low erythropoietin plasma levels during exacerbations of COPD. Respiration 2010;80:190-197.
121. Smith TG, Balanos GM, Croft QP, Talbot NP, Dorrington KL, Ratcliffe PJ, Robbins PA. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 2008;586:5999-6005.
122. Schoos MM, Dalsgaard M, Kjærgaard J, Moesby D, Jensen SG, Steffensen I, Iversen KK. Echocardiographic predictors of exercise capacity and mortality in chronic obstructive pulmonary disease. BMC Cardiovasc Disord 2013;13:84.
123. Steinbicker AU, Muckenthaler MU. Out of balance-systemic iron homeostasis in iron-related disorders. Nutrients 2013;5:3034-3061.
124. Van Buren P, Velez RL, Vaziri ND, Zhou XJ. Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol 2012;44:499-507.
125. DePalma RG, Zacharski LR, Chow BK, Shamayeva G, Hayes VW. Reduction of iron stores and clinical outcomes in peripheral arterial disease: outcome comparisons in smokers and non-smokers. Vascular 2013;21:233-241.
126. Martinez JA, Guerra CC, Nery LE, Jardim JR. Iron stores and coagulation parameters in patients with hypoxemic polycythemia secondary to chronic obstructive pulmonary disease: the effect of phlebotomies. Sao Paulo Med J 1997;115:1395-1402.
127. Chetty KG, Light RW, Stansbury DW, Milne N. Exercise performance of polycythemic chronic obstructive pulmonary disease patients. Effect of phlebotomies. Chest 1990;98:1073-1077.